 |
Early to Late Adolescence: Issues and Challenges in the Management of ADHD CME Andrew Adesman, MD; Doris Greenberg, MD; Susan Pratt, MD; Adelaide Robb, MD; David Goodman, MD; C. Brendan Montano, MD Author Information and Disclosures Release Date: February 5, 2008; Valid for credit through February 5, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | These newsletters are based on interviews and discussions with 6 expert clinicians. The first chapter will focus on challenges in managing attention-deficit/hyperactivity disorder (ADHD) in adolescents, the second will focus on the challenges of diagnosing and treating ADHD when it is accompanied by comorbidities, and the third will focus on optimizing physician-patient communication in adolescent ADHD.The content of this CME activity, "Early to Late Adolescence: Issues and Challenges in the Management of ADHD," was developed by the faculty.
To participate in this internet activity: 1) review the target audience, learning objectives and author disclosures, 2) study the educational content 3) answer the posttest and evaluation 4) view/print certificate View details Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 SynerMed® Communications.
SynerMed® Communications reserves copyright on all published materials, and such material may not be reproduced in any form without the written permission of SynerMed® Communications.
Jointly sponsored by Postgraduate Institute for Medicine and SynerMed® Communications. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Summarize the prevalence and the social and economic burden and consequences of ADHD
- Explain the presentation and comorbidities associated with ADHD in adolescent patients
- Discuss the use of screening instruments to aid in
detecting ADHD in adolescent patients
- List the available treatments for adolescent ADHD and their associated risks and benefits
- Outline practical approaches to daily communication with patients and caregivers
Authors and Disclosures Andrew Adesman, MD
Disclosure: Speaker's bureau: McNeil Consumer
& Specialty Pharmaceuticals, Novartis Pharmaceuticals Doris Greenberg, MD
Disclosure: Consulting fees: Abbott Laboratories, Bristol-Myers Squibb, McNeil Consumer & Specialty Pharmaceuticals, Novartis Pharmaceuticals, Shire, UCB Pharma; Speaker’s bureau: Bristol-Myers Squibb, McNeil Consumer & Specialty Pharmaceuticals, Novartis Pharmaceuticals, Shire, UCB Pharma
Susan Pratt, MD
Disclosure: No financial interest or other relationship with any manufacturer of any commercial product Adelaide Robb, MD
Disclosure: Grant/research support: Forest, Janssen, McNeil Consumer & Specialty Pharmaceuticals, Otsuka, Pfizer, Bristol-Myers Squibb; Speaker's bureau: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, McNeil
Consumer & Specialty Pharmaceuticals; Advisory board/Consultant: Eli Lilly and Company, Lundbeck, Otsuka David Goodman, MD
Disclosure: Research grants: Cephalon, Forest Laboratories, McNeil Consumer & Specialty Pharmaceuticals, New River Pharmaceuticals, Shire; Honoraria: Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, McNeil Consumer & Specialty Pharmaceuticals, Novartis
Pharmaceuticals, Shire, Wyeth; Speaker's bureau: Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, McNeil Consumer & Specialty Pharmaceuticals, Novartis Pharmaceuticals, Shire, Wyeth; Consultant: Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, McNeil Consumer & Specialty Pharmaceuticals, New River Pharmaceuticals, Novartis Pharmaceuticals, Shire C. Brendan Montano, MD
Disclosure: Disclosure: Research grants: AstraZeneca, Eli Lilly and Company, Forest Research Institute, Novartis Pharmaceuticals, sanofi-aventis, Schwarz Pharmaceuticals, Takeda, Wyeth Pharmaceuticals; Honoraria/consultant fees: AstraZeneca, Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, Wyeth; Speaker's bureau: AstraZeneca, Eli Lilly and Company The following SynerMed® staff, Otto Ratz, MD, Ronald Hoagland, and Jennifer
Lerner hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months.
The following PIM clinical content reviewers, Jan Hixon, RN, Linda Graham, RN, and Trace Hutchison, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months. |
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and SynerMed® Communications. PIM is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
